3-amino-2-diethylphosphonomethyloxy-5,6,7,8-tetrahydronaphthalene | 1055921-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3-amino-2-diethylphosphonomethyloxy-5,6,7,8-tetrahydronaphthalene
• 英文别名: 3-(Diethoxyphosphorylmethoxy)-5,6,7,8-tetrahydronaphthalen-2-amine
• CAS: 1055921-58-8
• 化学式: C₁₅H₂₄NO₄P
• 分子量: 313.334
• InChiKey: AWYRQJAGJPZOOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-amino-2-diethylphosphonomethyloxy-5,6,7,8-tetrahydronaphthalene 在 potassium thioacyanate 、 copper(II) sulfate 作用下， 以 甲醇 为溶剂， 生成 2-amino-4-diethylphosphonomethyloxy-5,6,7,8-tetrahydronaphtho[1,2-d]thiazole
  参考文献：
  名称：

  Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase

  摘要：

  公式I和X的FBPase抑制剂在治疗糖尿病和其他与血糖升高或多余糖原贮存有关的疾病中很有用。

  公开号：

  US06489476B1

文献信息

• Novel bisamidate phosphonate prodrugs
  申请人：METABASIS THERAPEUTICS, INC.

  公开号：US20020173490A1

  公开（公告）日：2002-11-21

  Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: 1 and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.

  新颖的双酰胺磷酸酯前药，用于治疗糖尿病和其他与血糖升高相关的疾病的Formula IA:1中的FBPase抑制剂及其用途。
• Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
  申请人：——

  公开号：US20040167178A1

  公开（公告）日：2004-08-26

  Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

  提供了含有FBPase抑制剂和胰岛素敏感剂的制药组合物，以及治疗糖尿病和对增加血糖控制、改善胰岛素敏感性、降低胰岛素水平或增强胰岛素分泌有反应的疾病的方法。
• Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
  申请人：——

  公开号：US20040058892A1

  公开（公告）日：2004-03-25

  Novel FBPase inhibitors of the formula I and X 1 are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

  化合物I和X1的新型FBPase抑制剂对于治疗糖尿病和其他与血糖升高有关的疾病是有用的。
• Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase
  申请人：Dang Qun

  公开号：US20070232571A1

  公开（公告）日：2007-10-04

  Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

  化学式为I和X的新型FBPase抑制剂在治疗糖尿病和其他与高血糖有关的疾病中有用。
• Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
  申请人：Erion D. Mark

  公开号：US20080004226A1

  公开（公告）日：2008-01-03

  Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

  提供含有FBPase抑制剂和胰岛素增敏剂的药物组合物，以及治疗糖尿病和对增加血糖控制、改善胰岛素敏感性、降低胰岛素水平或增强胰岛素分泌有反应的疾病的方法。